Literature DB >> 10541910

Nasal and ocular symptoms, tear film stability and biomarkers in nasal lavage, in relation to building-dampness and building design in hospitals.

G Wieslander1, D Norbäck, K Nordström, R Wålinder, P Venge.   

Abstract

OBJECTIVES: To study the relationships between dampness in concrete floors and building design on the one hand, and symptoms and medical signs of the eyes and nose in hospital workers, on the other.
METHODS: Four hospitals for geriatrics were selected to represent buildings with different ages and design, irrespective of symptom prevalence. The first building was built in 1925. The second, built in 1985, was known to have dampness in the floor. Conventional building techniques were used in the third building, built in 1993, and the last building was built in 1994, and was specially designed to include high ceilings, and minimal use of fluorescent lighting and interior plastic materials. The interior surfaces were painted with water-based beeswax glazing. All staff (n=95) working day shifts were invited to take part in a medical examination of the eyes and nose including acoustic rhinometry and nasal lavage, and a medical questionnaire, and 93% participated. Measurements of temperature, relative air humidity, air flow, illumination, volatile organic compounds (VOCs), molds, and bacteria were carried out in all buildings, together with measurements of formaldehyde, respirable dust, carbon monoxide (CO), carbon dioxide (CO(2)), nitrogen dioxide (NO(2)) and ozone. Statistical analyses were performed by bivariate analysis, and linear, ordinal, and logistic multiple regressions, adjusting for age, gender, tobacco smoking, atopy, and the perceived psychosocial work environment.
RESULTS: Dampness in the upper concrete floor surface (75-84%), ammonia under the floor [3 parts per million (ppm)], and 2-ethyl-1-hexanol in the air were detected in the two buildings built in 1985 and 1993. Increased occurrences of ocular and nasal symptoms, an increased concentration of lysozyme in nasal lavage, and decreased tear film stability were found in the subjects working in the damp buildings. Those in the specially designed building had fewer ocular and nasal symptoms, and increased tear film stability. All buildings had low levels of formaldehyde, molds, bacteria, ozone, and NO(2). The lowest total concentration of VOCs, and the highest concentration of specific VOCs of microbial origin, were found in the building with special design.
CONCLUSION: The study provides new evidence of the role of dampness-related alkaline degradation of di-(2-ethylhexyl) phthalate (DEHP) in polyvinyl chloride (PVC) building material. Emissions related to degradation of DEHP due to dampness in the floor, indicated by increased 2-ethyl-1-hexanol in the air, seem to increase both the secretion of lysozyme from the nasal mucosa and the occurrence of ocular and nasal symptoms. The indoor environment of the specially designed building with high ceilings and no fluorescent lighting or interior plastics seemed to have a positive influence on the nasal and ocular mucous membranes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10541910     DOI: 10.1007/s004200050398

Source DB:  PubMed          Journal:  Int Arch Occup Environ Health        ISSN: 0340-0131            Impact factor:   3.015


  26 in total

Review 1.  Eye complaints in the office environment: precorneal tear film integrity influenced by eye blinking efficiency.

Authors:  P Wolkoff; J K Nøjgaard; P Troiano; B Piccoli
Journal:  Occup Environ Med       Date:  2005-01       Impact factor: 4.402

2.  Symptoms in relation to chemicals and dampness in newly built dwellings.

Authors:  Y Saijo; R Kishi; F Sata; Y Katakura; Y Urashima; A Hatakeyama; S Kobayashi; K Jin; N Kurahashi; T Kondo; Y Y Gong; T Umemura
Journal:  Int Arch Occup Environ Health       Date:  2004-09-09       Impact factor: 3.015

3.  Exposure study to examine chemosensory effects of formaldehyde on hyposensitive and hypersensitive males.

Authors:  Joerg U Mueller; Thomas Bruckner; Gerhard Triebig
Journal:  Int Arch Occup Environ Health       Date:  2012-02-25       Impact factor: 3.015

4.  Insomnia is more common among subjects living in damp buildings.

Authors:  C Janson; D Norbäck; E Omenaas; T Gislason; L Nyström; R Jõgi; E Lindberg; M Gunnbjörnsdottir; E Norrman; T Wentzel-Larsen; C Svanes; E J Jensen; K Torén
Journal:  Occup Environ Med       Date:  2005-02       Impact factor: 4.402

5.  Experimental exposure to propylene glycol mist in aviation emergency training: acute ocular and respiratory effects.

Authors:  G Wieslander; D Norbäck; T Lindgren
Journal:  Occup Environ Med       Date:  2001-10       Impact factor: 4.402

6.  A field study on clinical signs and symptoms in cleaners at floor polish removal and application in a Swedish hospital.

Authors:  Gunilla Wieslander; Dan Norbäck
Journal:  Int Arch Occup Environ Health       Date:  2010-04-21       Impact factor: 3.015

7.  Indoor air quality and health problems associated with damp floor coverings.

Authors:  Anneli Tuomainen; Markku Seuri; Anne Sieppi
Journal:  Int Arch Occup Environ Health       Date:  2003-12-19       Impact factor: 3.015

8.  Indoor environment in dwellings, asthma, allergies, and sick building syndrome in the Swedish population: a longitudinal cohort study from 1989 to 1997.

Authors:  B Sahlberg; Y-H Mi; D Norbäck
Journal:  Int Arch Occup Environ Health       Date:  2009-07-19       Impact factor: 3.015

9.  Atopy, symptoms and indoor environmental perceptions, tear film stability, nasal patency and lavage biomarkers in university staff.

Authors:  Jan Vilhelm Bakke; Gunilla Wieslander; Dan Norbäck; Bente E Moen
Journal:  Int Arch Occup Environ Health       Date:  2007-12-08       Impact factor: 3.015

10.  Relationship between sick building syndrome and indoor environmental factors in newly built Japanese dwellings.

Authors:  Makoto Takeda; Yasuaki Saijo; Motoyuki Yuasa; Ayako Kanazawa; Atsuko Araki; Reiko Kishi
Journal:  Int Arch Occup Environ Health       Date:  2009-02-10       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.